苏黄止咳胶囊治疗感冒后咳嗽的Meta分析

Meta-analysis on Efficiency of Suhuang Zhike Capsule on Postinfectious Cough

关键词:  苏黄止咳胶囊  感冒后咳嗽  Meta分析

Key words:  Suhuang Zhike capsule  postinfectious cough  Meta analysis

摘要:

目的 评价苏黄止咳胶囊治疗感冒后咳嗽的临床疗效与安全性。方法 检索中国知网、万方、维普、中国生物医学文献数据库、Pubmed数据库和The Cochrane Library中关于苏黄止咳胶囊治疗感冒后咳嗽的临床随机对照试验，按照Cochrane系统评价手册推荐的方法评估纳入研究的偏倚风险，采用Review Manager 5.3软件进行Meta分析。结果 共纳入9个符合标准的RCT研究，共741例患者。纳入研究多数存在较高的方法学偏倚风险。Meta结果显示，①咳嗽总疗效治疗组优于对照组，差异有统计学意义[OR=3.43，95% CI（2.23，5.29），P<0.000 01]；②在咳嗽积分[SMD=-0.53，95% CI（-0.92，-0.15），P=0.007]、中医证候疗效[OR=2.64，95% CI为（1.32，5.31），P=0.006]上，苏黄止咳胶囊也均优于对照组，其差异均有统计学意义。③在咳嗽消失时间上，两组间差异有统计学意义[MD=-3.04，95% CI（-5.86，-0.22），P=0.03]，但在咳嗽起效时间上，2组间差异无统计学意义[SMD=-1.2，95% CI（-2.65，0.26），P=0.11]。④不良反应发生率治疗组和对照组差异无统计学意义[OR=0.91，95% CI（0.31，2.65），P=0.86]。结论 苏黄止咳胶囊治疗感冒后咳嗽疗效肯定，安全可靠。临床上具有一定的可替代性，但尚需更多大样本、高质量随机对照试验来证实。

Abstract:

OBJECTIVE To evaluate the clinical efficacy and safety of suhuang zhike capsule in the treatment of postinfectious cough. METHODS Retrieval of CNKI, Wanfang, VIP,CBM, Pubmed and The Cochrane Library on suhuang zhike capsule in the treatment of PIC clinical randomized controlled trials. Evaluate the risk of bias in the study of the method recommended by the Cochrane system. Used Review Manager 5.3 software to analysis. RESULTS A total of 9 studies were included in 741 patients. There was a higher risk of bias included in the study methodology majority. The result showed that:① The treatment group was better than the control group, the difference was statistically significant(OR=3.43, 95%CI(2.23, 5.29), P<0.000 01); ② On cough integration(SMD=-0.53, 95%CI(-0.92, -0.15), P=0.007), TCM syndrome(OR=2.64, 95%CI(1.32, 5.31), P=0.006), Suhuang Zhike capsules were also better than the control group, the differences were statistically significant. ③ There was significant difference between the two groups on cough disappearance time(MD=-3.04, 95%CI(-5.86, -0.22), P=0.03); But there was no significant difference between the two groups on cough onset time(SMD=-1.2, 95%CI(-2.65, 0.26), P=0.11). ④ The incidence of adverse reactions in the treatment group and the control group were not statistically significant(OR=0.91, 95%CI(0.31, 2.65), P=0.86). CONCLUSION Suhuang Zhike capsule treatment of PIC is effective, safe and reliable. The clinical practice has an alternative. But still need more large samples, high quality randomized controlled trials to be confirmed.